Anika Therapeutics, Inc. (ANIK)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 130 | 148 | 114 | 121 | 120 | 113 | 121 | 122 |
| Operating profit | $m | -11 | -5 | ||||||
| Net profit | $m | -24 | 4 | -15 | -83 | -56 | -11 | -4 | 15 |
| EPS reported | $ | -0.76 | -0.27 | ||||||
| Operating cashflow per share | $ | 0.78 | 0.45 | ||||||
| Capex per share | $ | 0.48 | 0.40 | ||||||
| FCF per share | $ | 0.30 | 0.04 | ||||||
| Free cash flow | $m | 4 | 1 | ||||||
| Net debt | $m | -33 | -15 | ||||||
| Book value equity | $m | 143 | 137 | ||||||
| Book value per share | $ | 10.01 | 10.22 | ||||||
| Number of shares | m | 14.34 | 13.43 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.96 | 1.00 | ||||||
| P/S LTM | x | 1.22 | 1.14 | ||||||
| P/FCF LTM | x | 31.59 | 245.19 | ||||||
| EV/EBITDA LTM | x | -29.78 | 39.22 | ||||||
| EV/Sales LTM | x | 0.94 | 2.18 | ||||||
| Earnings Yield LTM | % | -7.90% | -1.35% | ||||||
| FCF Yield | % | +3.17% | +0.41% | ||||||
| Quality | |||||||||
| ROE | % | -7.58% | -2.70% | ||||||
| ROIC | % | -6.48% | -3.17% | ||||||
| Operating margin | % | -9.80% | -4.24% | ||||||
| Gross margin | % | +56.56% | +62.16% | ||||||
| FCF/Sales | % | +3.87% | +0.47% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -5.91% | +0.62% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.17 | 0.02 | ||||||
| Net Debt/EBITDA | x | 8.73 | -5.56 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +17.56% | +8.37% | ||||||
| Net debt/Equity | x | -0.23 | -0.11 | ||||||
| Gross debt/equity | x | 0.18 | 0.17 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies. All of Anika's products are developed, manufactured, and commercialized utilizing their proprietary hyaluronic acid (HA) technology platform. Their comprehensive product lines feature an OA pain management family, which includes established treatments like Monovisc, Orthovisc, Cingal, and Hyvisc, all designed to alleviate discomfort from osteoarthritis. The company's joint preservation and restoration offerings are extensive, comprising approximately 150 bone-sparing joint technology products, alongside solutions for sports medicine soft tissue repair and orthopedic regenerative therapies. Furthermore, Anika leverages its HA expertise in a non-orthopedic product family, developing applications such as adhesion barriers, advanced wound care products, ophthalmic solutions, and ear, nose, and throat treatments. Anika Therapeutics, Inc. was established in 1983 and is based in Bedford, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free